To test the hypothetical idea, therefore, future studies are expected to address at the single cell level the question of whether reduction of GLUT1 expression and glucose uptake actually precedes cell death in individual cells destined to undergo cell death, as well as the question of whether NSCLC cells with activating EGFR mutations are more susceptible to GLUT1 inhibition by gefitinib. The gene discussed is SLC2A1; the disease is non-small cell lung carcinoma.